RxDoctor Payments Data

Stephanie Sumner, APRN

Family · London, KYNPI 1013550060

Payments from drug & device makers

$864in general payments, 2019–2025

Across 49 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$206
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$114
  • Scilex Pharmaceuticals Inc.$103
  • Lilly USA, LLC$97
  • Vanda Pharmaceuticals Inc.$64
  • Biohaven Pharmaceutical Holding Company Ltd.$59
  • plus $220 from 11 others

What the payments were for

  • Food & beverage$864100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$864 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,265
Medicare patients
30
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$114,606
MounjaroTirzepatide81$89,444
JardianceEmpagliflozin71$71,118
JanuviaSitagliptin Phosphate37$38,266
LinzessLinaclotide36$34,693
TrulicityDulaglutide13$17,573
EntrestoSacubitril/Valsartan15$12,914
FarxigaDapagliflozin Propanediol12$12,589
JanumetSitagliptin Phos/Metformin Hcl13$8,536
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$6,259
SymbicortBudesonide/Formoterol Fumarate18$3,860
Albuterol Sulfate HfaAlbuterol Sulfate75$2,980
Dexlansoprazole DrDexlansoprazole13$2,052
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen107$1,730
Ventolin HfaAlbuterol Sulfate23$1,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$114,606117 claims
Lilly USA, LLCMounjaro, Trulicity$97$107,01694 claims
Boehringer IngelheimJardiance$17$71,11871 claims
AbbVieLinzess$206$34,69336 claims
AstraZenecaFarxiga, Symbicort$31$16,44930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in London

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →